Annual financial results as of 31 December, 2025
13/05/2026 – AB Science reports its revenues for the year 2025 and provides an update on its activities
Read more
therapies in diseases
with high medical need
Latest news
AB Science announces the successful completion of a EUR 3.2 million private placement
29/04/2026 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 3.2 million subscribed by a limited number of investors
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors
27/04/2026 – AB Science announces today that a final agreement has been reached with its financial creditors for the 24-month deferral of repayment of its bank debt and the 12-month deferral of repayment of a loan subscribed with the EIB
New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
20/04/2026 – AB Science announced the publication of a new article on the preprint platform medRxiv, evaluating long-term ALS survivors treated with masitinib at 4.5 mg/kg/day in the phase 2b/3 AB10015 study
Update on clinical development program
16/04/2026 – AB Science provides an update on its clinical development program
AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS
24/02/2026 – AB Science announced the identification of a potential biomarker for assessing the activity of masitinib in pathological microglial involvement in Amyotrophic Lateral Sclerosis (ALS)